Intra-Cellular Therapies Inc.
ITCI
NGS
Sector: Healthcare
Industry: Biotechnology
47.76
USD
1.23
(2.64%)
Optionable: Yes Market Cap: 4,208 M 90-day average vol: 733,042
Previous close: 46.53 Open: 46.53 Bid: 48.61 Ask: 48.61
52 week range
34.43 66.00
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 30.73 |
Price per Book TTM ($) | 5.58 |
PE Ratio (TTM) | -11.50 |
Book Value per Share ($) | 7.65 |
5 Year PE Range-14.9 |
Returns
7 Day Return | 11.85% | |
1 Month Return | -5.95% | |
3 Month Return | -16.34% | |
1 Year Return | 21.03% | |
3 Year Return | 485.29% | |
5 Year Return | 186.67% | |
YTD Return | -8.75% |
Risk
Custom Beta One Year | 0.72 |
Custom Beta Three Years | 1.00 |
Beneish M Score | -1.01 |
Altman Z Score | 25.44 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 48.52 |
14 Day SMA ($) | 46.29 |
14 Day EMA ($) | 46.69 |
Money Flow Index | 70.54 |
Average True Range | 2.19 |
50 Day SMA ($) | 51.09 |
200 Day SMA ($) | 53.30 |
ADX | 48.84 |
MACD | -1.65 |
Growth
Free Cash Flow QoQ Growth | 13.79% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 17.95% |
Revenue QoQ Growth | 58.46% |
EPS YoY Growth | 0.00% |
Profitability
News
Financials
ITCI Income Statement
Annual
| Mar-13 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 3 M | 547546 | 30659 | 330702 | 245837 | 0 | 0 | 23 M | 82 M |
| Cost of sales | 0 | -23249 | -322704 | -852301 | -741226 | -643711 | 574566 | 654476 | 2 M | 12 M |
| Gross operating profit | 0 | 3 M | 547546 | 30659 | 330702 | 245837 | 0 | 0 | 21 M | 74 M |
| Selling Gen & administrative expense | 32100 | 6 M | 10 M | 18 M | 25 M | 23 M | 30 M | 65 M | 186 M | 271 M |
| Research & development expense | 15 M | 23 M | 21 M | 88 M | 94 M | 79 M | 132 M | 89 M | 66 M | 89 M |
| Operating income | -32100 | -26 M | -31 M | -106 M | -118 M | -103 M | -162 M | -154 M | -231 M | -286 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income (EBT) | -32100 | -27 M | -31 M | -105 M | -115 M | -99 M | -155 M | -148 M | -227 M | -284 M |
| Income taxes | 0 | 18000 | 1600 | 1600 | 1 M | -1 M | 1600 | 1600 | 13513 | 5631 |
| Net income from total operations | -32100 | -27 M | -31 M | -105 M | -116 M | -98 M | -155 M | -148 M | -227 M | -284 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -32100 | -27 M | -31 M | -105 M | -116 M | -98 M | -155 M | -148 M | -227 M | -284 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -32100 | -27 M | -31 M | -105 M | -116 M | -98 M | -155 M | -148 M | -227 M | -284 M |
| Depreciation | 0 | 23249 | 322704 | 852301 | 741226 | 643711 | -574566 | -654476 | -120130 | -4 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -32100 | -26 M | -31 M | -105 M | -115 M | -102 M | -162 M | -154 M | -231 M | -285 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0 | -1.56 | -1.07 | -2.91 | -2.69 | -2.12 | -2.84 | -2.68 | -3.23 | -3.5 |
| Diluted EPS total | 0 | -1.56 | -1.07 | -2.91 | -2.69 | -2.12 | -2.84 | -2.68 | -3.23 | -3.5 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today